This COVID-19 roundup includes coverage of the FDA’s guidance for the correct Moderna vaccine dosage for pediatric patients, COVID-19 outcomes for patients with hypertension and diabetes, and the risk of...
Earlier this year, the FDA approved the same vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
Following three clinical trials, the FDA has approved a new preventive treatment for neonates, infants, and toddlers that prevents respiratory syncytial virus (RSV) in those age populations.
A multi-institutional retrospective cohort study presented at the American Heart Association Scientific Sessions 2025 found that adults with respiratory syncytial virus infection faced a nearly fourfold...
In this respiratory disease roundup, researchers highlight the efficacy of clesrovimab in preventing respiratory syncytial virus infections in infants, the influenza vaccine's updated formulation this virus...
